| Ytd | -25.39% | |
| 1y | -26.90% |
| Open | 1.38 | Prev Close | 1.36 | Low | 1.38 | High | 1.46 | Mkt Cap | 21.57M |
| Vol | 0.00 | Avg Vol | 244.82K | EPS | -0.95 | P/E | -1.52 | Forward P/E | -2.35 |
| Beta | 1.34 | Short Ratio | 0.64 | Inst. Own | 7.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.81 | 200-d Avg | 1.92 | 1yr Est | 21.33 |
DARE News
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercialization Highlights on
A featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtu
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven
Live video webcast on Tuesday, July 14th, at 4:00 PM ETRegister here SAN DIEGO, July 09, 2026 (GLOBE
Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's He
First consumer health product positions Daré for revenue generation while expanding its women's heal
President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present
Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding aw
Each year, an estimated six million women in the United States acquire a high-risk HPV infection — a
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial
Shares of Dare Bioscience, Inc. (NASDAQ:DARE) are trading higher on Tuesday as the company is report
Second Positive DSMB Review Supports Continued Study Progress Interim Phase 3 Results Support Ovapre
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.02 per share versus the Zacks Cons
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health S
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quart
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin
Friday's session saw 225 companies set new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.
On Tuesday, 164 companies achieved new lows for the year.
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quart
On Tuesday, 298 companies achieved new lows for the year.
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings
During Wednesday's trading, 517 companies set new 52-week lows.
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to repor